Related references
Note: Only part of the references are listed.Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen et al.
NATURE BIOTECHNOLOGY (2012)
Disulfide-Linked Antibody-Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage
Brenda A. Kellogg et al.
BIOCONJUGATE CHEMISTRY (2011)
SNAP-Tag Technology Mediates Site Specific Conjugation of Antibody Fragments with a Photosensitizer and Improves Target Specific Phototoxicity in Tumor Cells
Ahmad Fawzi Hussain et al.
BIOCONJUGATE CHEMISTRY (2011)
Selective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
Benjamin M. Hutchins et al.
CHEMISTRY & BIOLOGY (2011)
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart
CLINICAL CANCER RESEARCH (2011)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2011)
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy
Massimo Breccia et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia
Marie-Luise Huetter et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
Howard A. Burris
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Investigational antibody-drug conjugates for hematological malignancies
Andrew G. Polson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
Stephen M. Ansell
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
The development of pyrrolobenzodiazepines as antitumour agents
John A. Hartley
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Investigational antibody drug conjugates for solid tumors
Puja Sapra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor
Arehalli S. Manjappa et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody
In Soo Shin et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Bispecific digoxigenin-binding antibodies for targeted payload delivery
Silke Metz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Franco Dosio et al.
TOXINS (2011)
Ranking the Susceptibility of Disulfide Bonds in Human IgGs1 Antibodies by Reduction, Differential Alkylation, and LC-MS Analysis
Hongcheng Liu et al.
ANALYTICAL CHEMISTRY (2010)
Design and Application of Antibody Cysteine Variants
Vladimir Voynov et al.
BIOCONJUGATE CHEMISTRY (2010)
Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes
Aditya A. Wakankar et al.
BIOCONJUGATE CHEMISTRY (2010)
Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Laurent Ducry et al.
BIOCONJUGATE CHEMISTRY (2010)
Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size
Christian Zahnd et al.
CANCER RESEARCH (2010)
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena V. Kovtun et al.
CANCER RESEARCH (2010)
Inotuzumab ozogamicin as novel therapy in lymphomas
Bryan Y. Wong et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Neonatal Fc Receptor: From Immunity to Therapeutics
Timothy T. Kuo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Have we overestimated the benefit of human(ized) antibodies?
Daniel R. Getts et al.
MABS (2010)
Mining human antibody repertoires
Roger R. Beerli et al.
MABS (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
The Versatile MHC Class I-related FcRn Protects IgG and Albumin from Degradation: Implications for Development of New Diagnostics and Therapeutics
Jan Terje Andersen et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Industrialization of mAb production technology The bioprocessing industry at a crossroads
Brian Kelley
MABS (2009)
A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution
Fares Al-Ejeh et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
Ravi V. J. Chari
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Greg M. Thurber et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass
Thomas M. Dillon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
Jagath R. Junutula et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
An engineered selenocysteine defines a unique class of antibody derivatives
Thomas Hofer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering
David P. Humphreys et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2007)
Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge
Sibu Balan et al.
BIOCONJUGATE CHEMISTRY (2007)
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C. Widdison et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Targeted therapy of cancer: New prospects for antibodies and immunoconjugates
Robert M. Sharkey et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2006)
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte F. McDonagh et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody
FR Taylor et al.
ANALYTICAL BIOCHEMISTRY (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Structural characterization of the maytansinoid -: monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
LT Wang et al.
PROTEIN SCIENCE (2005)
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
MMC Sun et al.
BIOCONJUGATE CHEMISTRY (2005)
Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
JF DiJoseph et al.
CLINICAL CANCER RESEARCH (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Mono-N-terminal poly(ethylene glycol)-protein conjugates
O Kinstler et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Enzymatic procedure for site-specific pegylation of proteins
H Sato
ADVANCED DRUG DELIVERY REVIEWS (2002)
Antibody-targeted immunotherapy for treatment of malignancy
CA White et al.
ANNUAL REVIEW OF MEDICINE (2001)
Site-specific conjugation on serine → cysteine variant monoclonal antibodies
JB Stimmel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
